# JAMA Neurology : Gefurulimab and Generalized Myasthenia Gravis

Page: https://stenobird.com/podcast/jama-network-1057758/jama-neurology-gefurulimab-and-generalized-myasthenia-gravis
Text version: https://stenobird.com/podcast/jama-network-1057758/jama-neurology-gefurulimab-and-generalized-myasthenia-gravis.md
Podcast: [JAMA Network](https://stenobird.com/podcast/jama-network-1057758)
Published: 2026-07-27T15:00:00+00:00
Episode link: https://edhub.ama-assn.org/jn-learning/audio-player/10.1001/jamaneurol.2026.2687
Audio file: http://traffic.libsyn.com/jamaneurologyauthorinterviews/Gefurulimab_and_Generalized_Myasthenia_Gravis_1.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/jama-network-1057758/episodes/jama-neurology-gefurulimab-and-generalized-myasthenia-gravis
Duration seconds: 1002

## Resource

Interview with Kelly G. Gwathmey, MD, author of Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis Gefurulimab—The First Effective Nanobody in Myasthenia Gravis Therapy

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/jama-network-1057758/episodes/jama-neurology-gefurulimab-and-generalized-myasthenia-gravis/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/jama-network-1057758/jama-neurology-gefurulimab-and-generalized-myasthenia-gravis.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.